JP7273455B1 - 新型コロナウイルス感染症治療用医薬 - Google Patents

新型コロナウイルス感染症治療用医薬 Download PDF

Info

Publication number
JP7273455B1
JP7273455B1 JP2023511553A JP2023511553A JP7273455B1 JP 7273455 B1 JP7273455 B1 JP 7273455B1 JP 2023511553 A JP2023511553 A JP 2023511553A JP 2023511553 A JP2023511553 A JP 2023511553A JP 7273455 B1 JP7273455 B1 JP 7273455B1
Authority
JP
Japan
Prior art keywords
cov
sars
day
covid
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023511553A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023054732A1 (https=
JPWO2023054732A5 (https=
Inventor
亮輔 清水
裕美子 松尾
章浩 福原
圭太 深尾
隆之 黒田
治謙 登
徹 石橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of JPWO2023054732A1 publication Critical patent/JPWO2023054732A1/ja
Priority to JP2023072576A priority Critical patent/JP2023105826A/ja
Application granted granted Critical
Publication of JP7273455B1 publication Critical patent/JP7273455B1/ja
Publication of JPWO2023054732A5 publication Critical patent/JPWO2023054732A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023511553A 2022-01-19 2023-01-18 新型コロナウイルス感染症治療用医薬 Active JP7273455B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023072576A JP2023105826A (ja) 2022-01-19 2023-04-26 新型コロナウイルス感染症治療用医薬

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
JP2022006725 2022-01-19
JP2022006725 2022-01-19
JP2022012386 2022-01-28
JP2022012386 2022-01-28
JP2022017132 2022-02-07
JP2022017132 2022-02-07
JP2022027629 2022-02-25
JP2022027629 2022-02-25
JP2022120325 2022-07-28
JP2022120325 2022-07-28
JP2022149666 2022-09-21
JP2022149666 2022-09-21
PCT/JP2023/001243 WO2023054732A2 (ja) 2022-01-19 2023-01-18 新型コロナウイルス感染症治療用医薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023072576A Division JP2023105826A (ja) 2022-01-19 2023-04-26 新型コロナウイルス感染症治療用医薬

Publications (3)

Publication Number Publication Date
JPWO2023054732A1 JPWO2023054732A1 (https=) 2023-04-06
JP7273455B1 true JP7273455B1 (ja) 2023-05-15
JPWO2023054732A5 JPWO2023054732A5 (https=) 2023-09-06

Family

ID=85780780

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023511553A Active JP7273455B1 (ja) 2022-01-19 2023-01-18 新型コロナウイルス感染症治療用医薬
JP2023072576A Pending JP2023105826A (ja) 2022-01-19 2023-04-26 新型コロナウイルス感染症治療用医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023072576A Pending JP2023105826A (ja) 2022-01-19 2023-04-26 新型コロナウイルス感染症治療用医薬

Country Status (7)

Country Link
US (1) US20250099474A1 (https=)
EP (1) EP4467142A4 (https=)
JP (2) JP7273455B1 (https=)
KR (1) KR20240137021A (https=)
AU (1) AU2023202177A1 (https=)
MX (1) MX2024008910A (https=)
WO (1) WO2023054732A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
LT4122926T (lt) 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
WO2024031089A1 (en) 2022-08-05 2024-02-08 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509140A (ja) * 1998-01-13 2002-03-26 アナディーズ・ファーマスーティカルズ，インコーポレイテッド トリアジン抗ウイルス化合物
WO2019087884A1 (ja) * 2017-10-31 2019-05-09 富士フイルム株式会社 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
WO2022138988A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
WO2022158528A1 (ja) * 2021-01-20 2022-07-28 国立大学法人北海道大学 抗ウイルス剤
WO2022212314A1 (en) * 2021-03-29 2022-10-06 Shireen Nature Company For General Trading, Ltd. Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions
JP7236065B1 (ja) * 2021-09-28 2023-03-09 塩野義製薬株式会社 トリアジン誘導体を含有する医薬組成物
JP7253866B1 (ja) * 2021-11-24 2023-04-07 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2399910T3 (pl) * 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
CN103153968B (zh) 2010-08-10 2016-02-03 盐野义制药株式会社 三唑衍生物及含有其的具有镇痛作用的药物组合物
JP6075621B2 (ja) 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
TW201331188A (zh) 2011-12-15 2013-08-01 Shionogi & Co 經取代之三□衍生物及含有其之醫藥組成物
WO2013118855A1 (ja) 2012-02-09 2013-08-15 塩野義製薬株式会社 複素環および炭素環誘導体
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509140A (ja) * 1998-01-13 2002-03-26 アナディーズ・ファーマスーティカルズ，インコーポレイテッド トリアジン抗ウイルス化合物
WO2019087884A1 (ja) * 2017-10-31 2019-05-09 富士フイルム株式会社 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
WO2022158528A1 (ja) * 2021-01-20 2022-07-28 国立大学法人北海道大学 抗ウイルス剤
WO2022212314A1 (en) * 2021-03-29 2022-10-06 Shireen Nature Company For General Trading, Ltd. Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions
WO2022138988A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
WO2022138987A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
JP7105430B1 (ja) * 2021-04-14 2022-07-25 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
JP7236065B1 (ja) * 2021-09-28 2023-03-09 塩野義製薬株式会社 トリアジン誘導体を含有する医薬組成物
JP7253866B1 (ja) * 2021-11-24 2023-04-07 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU, Y. et al.，The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020，European Journal of Medicinal Chemistry，2020年，206，112711(p.1-18)
LIU, Y. ET AL.: "The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 206, JPN6022052098, 2020, pages 1 - 18, ISSN: 0005040914 *

Also Published As

Publication number Publication date
WO2023054732A3 (ja) 2023-06-15
KR20240137021A (ko) 2024-09-19
TW202339757A (zh) 2023-10-16
US20250099474A1 (en) 2025-03-27
EP4467142A2 (en) 2024-11-27
JPWO2023054732A1 (https=) 2023-04-06
JP2023105826A (ja) 2023-07-31
MX2024008910A (es) 2024-07-25
AU2023202177A1 (en) 2024-07-18
WO2023054732A2 (ja) 2023-04-06
EP4467142A4 (en) 2025-12-31

Similar Documents

Publication Publication Date Title
JP7273455B1 (ja) 新型コロナウイルス感染症治療用医薬
TWI815396B (zh) 具有病毒增殖抑制作用之三嗪衍生物及含有其等之醫藥組合物
JP7253866B1 (ja) トリアジン誘導体を含有する経口投与する製剤
WO2023054292A1 (ja) トリアジン誘導体を含有する医薬組成物
JP6618901B2 (ja) インフルエンザウイルスの複製の阻害剤を調製する方法
RU2700415C1 (ru) Ингибиторы репликации вирусов гриппа
JP7236065B1 (ja) トリアジン誘導体を含有する医薬組成物
US20250025459A1 (en) Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug
CN116514734A (zh) 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂
WO2023033098A1 (ja) ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
CN116782904A (zh) 含有三嗪衍生物的医药组合物
TWI916636B (zh) 新型冠狀病毒感染症治療用醫藥
HK40116243A (en) Pharmaceutical for treating novel coronavirus infection
CN117120057A (zh) 新型冠状病毒传染病治疗用药物
JP7674711B1 (ja) ウラシル誘導体を含有する医薬組成物
HK40114521A (en) Pharmaceutical composition containing triazine derivative
WO2025074997A1 (ja) ウイルス増殖阻害活性を有する縮合複素環誘導体およびそれらを含有する医薬組成物
WO2020256820A1 (en) Formulations of azaindole compounds

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20230214

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20230215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230317

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230426

R150 Certificate of patent or registration of utility model

Ref document number: 7273455

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250